Insulin glulisine in the management of diabetes

Diabetes, Metabolic Syndrome and Obesity

Volumn 2, Issue , 2009, Pages 111-115

  Yamada, Satoru ^a,b  

^a KITASATO INSTITUTE HOSPITAL   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Insulin analog; Polysorbate 20; Rapid acting insulin; Trometamol

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW;

EID: 77953435865     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmsott.s3404     Document Type: Review

References (34)

1. The Diabetes Control and Complications Trial (DCCT) Research Group; The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
2. UK Prospective Diabetes Study (UKPDS) Group; Intensive bloodglucose control with sulphonylureas of insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet. 1998;352(9131):837-853.
3. UK Prospective Diabetes Study (UKPDS) Group; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet. 1998;352(9131):854-865.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group; Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
5. The ADVANCE Collaborative Group; Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
7. Maedler K, Donath MY. Beta-cells in type 2 diabetes: a loss of function and mass. Horm Res. 2004;62 Suppl 3:S67-S73.
8. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782-787.
9. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13(9): 923-954.
10. Wilde MI, McTavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs. 1997;54(4):597-614.
11. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001;40(9):641-659.
12. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47(1):7-20.
13. Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007;9(1):109-121.
14. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid timeaction profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes. 2005;113(8):435-443.
15. Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9(5):746-753.
16. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR. A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period. Diabetes Res Clin Pract. 2008;79(2): 269-275.
17. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro. Diabetes Care. 2003;26(7): 2027-2031.
18. Horvath K, Bock G, Regittnig W, et al. Insulin glulisine, insulin lispro and regular human insulin chow comparable end-organ metabolic effects: an exploratory study. Diabetes Obes Metab. 2008;10(6): 484-491.
19. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;19(2):CD003287.
20. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005; 11(1):11-17.
21. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27(10):2363-2368.
22. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res. 2005; 37(11):702-707.
23. Hoogma RPL, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006;38(6):429-433.
24. Johansson UB, Adamson UC, Lins PE, Wredling RA. Improved blood glucose variability, HbA1c insuman infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter lispro insulin study. Diabetes Metab. 2000;26(3):192-196.
25. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med. 2000;17(3):209-214.
26. Ferguson SC, Strachan MW, Janes JM, Frier BM. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes Metab Res Rev. 2001;17(4):285-291.
27. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. Diabetes Care. 1999;22(5): 784-788.
28. Home PD, Lindholm A, Riis A. Insulin aspart vs human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17(11): 762-770.
29. Bott U, Ebrahim S, Hirschberger S. Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med. 2003;20(8):626-634.
30. Annuzzi G, Del Prato S, Arcari R, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr Metab Carciovasc Dis. 2001;11(3):168-175.
31. Ottesen JL, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia. 1994;37(12):1178-1185.
32. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [(Lys(B28), Pro(B29) human insulin)] in IDDM and NIDDM patients previously treated with insulin. Diabetes. 1996;45(12):1750-1754.
33. Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care. 2003;26(1):89-96.
34. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;22(5):876-882.